Back to Search Start Over

SARS-CoV-2 infection, vaccination, and antibody response trajectories in adults: a cohort study in Catalonia

Authors :
Marianna Karachaliou
Gemma Moncunill
Ana Espinosa
Gemma Castaño-Vinyals
Rocío Rubio
Marta Vidal
Alfons Jiménez
Esther Prados
Anna Carreras
Beatriz Cortés
Natàlia Blay
Marc Bañuls
Vanessa Pleguezuelos
Natalia Rodrigo Melero
Pau Serra
Daniel Parras
Luis Izquierdo
Pere Santamaría
Carlo Carolis
Kyriaki Papantoniou
Ximena Goldberg
Ruth Aguilar
Judith Garcia-Aymerich
Rafael de Cid
Manolis Kogevinas
Carlota Dobaño
Source :
BMC Medicine, Vol 20, Iss 1, Pp 1-16 (2022)
Publication Year :
2022
Publisher :
BMC, 2022.

Abstract

Abstract Background Heterogeneity of the population in relation to infection, COVID-19 vaccination, and host characteristics is likely reflected in the underlying SARS-CoV-2 antibody responses. Methods We measured IgM, IgA, and IgG levels against SARS-CoV-2 spike and nucleocapsid antigens in 1076 adults of a cohort study in Catalonia between June and November 2020 and a second time between May and July 2021. Questionnaire data and electronic health records on vaccination and COVID-19 testing were available in both periods. Data on several lifestyle, health-related, and sociodemographic characteristics were also available. Results Antibody seroreversion occurred in 35.8% of the 64 participants non-vaccinated and infected almost a year ago and was related to asymptomatic infection, age above 60 years, and smoking. Moreover, the analysis on kinetics revealed that among all responses, IgG RBD, IgA RBD, and IgG S2 decreased less within 1 year after infection. Among vaccinated, 2.1% did not present antibodies at the time of testing and approximately 1% had breakthrough infections post-vaccination. In the post-vaccination era, IgM responses and those against nucleoprotein were much less prevalent. In previously infected individuals, vaccination boosted the immune response and there was a slight but statistically significant increase in responses after a 2nd compared to the 1st dose. Infected vaccinated participants had superior antibody levels across time compared to naïve-vaccinated people. mRNA vaccines and, particularly the Spikevax, induced higher antibodies after 1st and 2nd doses compared to Vaxzevria or Janssen COVID-19 vaccines. In multivariable regression analyses, antibody responses after vaccination were predicted by the type of vaccine, infection age, sex, smoking, and mental and cardiovascular diseases. Conclusions Our data support that infected people would benefit from vaccination. Results also indicate that hybrid immunity results in superior antibody responses and infection-naïve people would need a booster dose earlier than previously infected people. Mental diseases are associated with less efficient responses to vaccination.

Details

Language :
English
ISSN :
17417015
Volume :
20
Issue :
1
Database :
Directory of Open Access Journals
Journal :
BMC Medicine
Publication Type :
Academic Journal
Accession number :
edsdoj.b0dca03d882e40fab8ed0042d19a05bf
Document Type :
article
Full Text :
https://doi.org/10.1186/s12916-022-02547-2